Related Experiment Video
Updated: Aug 8, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment
Navreet K Nanda1, Lynn Birch, Norman M Greenberg
1Department of Microbiology, Georgetown University Medical Center, Washington, District of Columbia, USA. nandan@niaid.nih.gov
Background:
There has been a determined search for therapies specifically aimed at eradicating tumor cells while leaving normal host cells unaffected. This goal can potentially be accomplished by engaging tumor antigen-specific T-cell repertoire to attack the tumor. A pre-requisite for a successful T-cell-mediated attack against tumors or pathogens is that the target tissues express major histocompatibility complex (MHC) molecules. Using newer anti-MHC class I and MHC class II antibody reagents, we re-examined the expression of MHC in both human and mouse prostate tumors and their microenvironments.
Methods:
Using immunocytochemistry, we examined the expression of MHC class I, class II, and CD3 molecules on cryopreserved human and mouse prostate tumor samples.
Results:
MHC class I molecules are expressed by the entire spectrum of different stages of both human and mouse prostate tumor cells. Additionally, cells of the hematopoietic lineage, dispersed in the tumor microenvironment, showed significant expression of MHC class II molecules. Human prostate tumors also show a significant infiltrate of CD3+ T cells.
Conclusions:
Expression of MHC class I and class II molecules within the prostate tumor microenvironment are consequential for T-cell-mediated immunotherapeutic approaches against prostate cancer.
Insights
Major histocompatibility complex (MHC) class I and II molecules are expressed in prostate tumors, supporting T-cell immunotherapy. This research confirms MHC expression is crucial for effective T-cell-mediated prostate cancer treatments.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Developing targeted cancer therapies that spare normal cells is a key goal in oncology.
- Engaging the body's own T-cells to attack tumors requires the tumor cells to express specific markers.
- Major histocompatibility complex (MHC) molecules are essential for T-cell recognition of target cells.
Purpose of the Study:
- To investigate the expression of MHC class I and MHC class II molecules in human and mouse prostate tumors.
- To assess the presence of CD3+ T-cells within the tumor microenvironment.
- To determine the relevance of MHC expression for T-cell-mediated immunotherapies in prostate cancer.
Main Methods:
- Immunocytochemistry was employed to analyze cryopreserved human and mouse prostate tumor samples.
- Expression levels of MHC class I, MHC class II, and CD3 molecules were quantified.
Main Results:
- MHC class I molecules were consistently expressed across all stages of both human and mouse prostate tumors.
- Hematopoietic cells within the tumor microenvironment exhibited significant MHC class II expression.
- Human prostate tumors demonstrated a notable infiltration of CD3+ T-cells.
Conclusions:
- The presence of MHC class I and class II molecules in the prostate tumor microenvironment is critical.
- These findings underscore the importance of MHC expression for successful T-cell-mediated immunotherapeutic strategies against prostate cancer.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:17The Tumor Microenvironment